Published in Oncoimmunology on December 13, 2014
Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma | NCT01811992
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell (2016) 1.21
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget (2015) 1.05
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget (2015) 0.95
The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle (2015) 0.91
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget (2015) 0.89
First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology (2015) 0.88
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood (2016) 0.86
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology (2015) 0.86
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology (2015) 0.85
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology (2015) 0.85
Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. Transl Oncol (2016) 0.84
Calreticulin as cancer treatment adjuvant: combination with photodynamic therapy and photodynamic therapy-generated vaccines. Front Oncol (2015) 0.84
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget (2015) 0.83
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83
Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget (2016) 0.82
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ (2016) 0.82
Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med (2016) 0.82
Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene (2015) 0.82
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Cell death, clearance and immunity in the skeletal muscle. Cell Death Differ (2016) 0.81
Stimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cells. Oncotarget (2015) 0.80
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med (2016) 0.80
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med (2016) 0.80
Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis. Oncoimmunology (2015) 0.80
CD4(+)FOXP3(+) T regulatory cells decrease and CD3(+)CD8(+) T cells recruitment in TILs from melanoma metastases after electrochemotherapy. Clin Exp Metastasis (2016) 0.79
Novel function of cytoplasmic p53 at the interface between mitochondria and the endoplasmic reticulum. Cell Death Dis (2015) 0.79
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol (2017) 0.79
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma. Curr Neurol Neurosci Rep (2016) 0.78
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol (2016) 0.78
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front Immunol (2016) 0.78
Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. Oncoimmunology (2015) 0.78
Editorial: Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality. Front Immunol (2016) 0.78
Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology (2015) 0.78
STAT3 inhibition for cancer therapy: Cell-autonomous effects only? Oncoimmunology (2016) 0.78
Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants. Viruses (2015) 0.78
Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget (2017) 0.78
Viroimmunotherapy of Thoracic Cancers. Biomedicines (2017) 0.77
Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology (2015) 0.77
Immunoregulatory Cell Depletion Improves the Efficacy of Photodynamic Therapy-Generated Cancer Vaccines. Int J Mol Sci (2015) 0.77
Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. Oncoimmunology (2015) 0.77
Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget (2016) 0.77
Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. Oncoimmunology (2016) 0.76
Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. Oncoimmunology (2016) 0.76
Improvement of immunogenic chemotherapy by STAT3 inhibition. Oncoimmunology (2015) 0.76
Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet. Front Oncol (2016) 0.76
Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. Oncoimmunology (2016) 0.76
The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncoimmunology (2016) 0.76
Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system. Oncotarget (2017) 0.75
Hypericin in the Dark: Foe or Ally in Photodynamic Therapy? Cancers (Basel) (2016) 0.75
Evolution of normal and neoplastic tissue stem cells: progress after Robert Hooke. Philos Trans R Soc Lond B Biol Sci (2015) 0.75
Cell-in-cell structures are more potent predictors of outcome than senescence or apoptosis in head and neck squamous cell carcinomas. Radiat Oncol (2017) 0.75
Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. Oncoimmunology (2017) 0.75
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer J (2016) 0.75
Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model. Cell Death Dis (2016) 0.75
Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck. Front Oncol (2016) 0.75
Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells. Genes Cancer (2017) 0.75
DNA Damage Response and Autophagy: A Meaningful Partnership. Front Genet (2016) 0.75
Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. Cell Death Differ (2017) 0.75
Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model. BMC Immunol (2016) 0.75
Hyperthermic intra-peritoneal chemotherapy and anticancer immune response. Oncoimmunology (2015) 0.75
N-Dihydrogalactochitosan as a potent immune activator for dendritic cells. J Biomed Mater Res A (2016) 0.75
In Vitro Cell Death Determination for Drug Discovery: A Landscape Review of Real Issues. J Cell Death (2017) 0.75
Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. Oral Oncol (2016) 0.75
Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. Mol Ther Oncolytics (2016) 0.75
The P2X7 Receptor-Interleukin-1 Liaison. Front Pharmacol (2017) 0.75
Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death. J Immunother Cancer (2017) 0.75
Calreticulin and type I interferon: An unsuspected connection. Oncoimmunology (2017) 0.75
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol (2015) 0.75
Melanoma targeting with the loco-regional chemotherapeutic, Melphalan: From cell death to immunotherapeutic efficacy. Oncoimmunology (2015) 0.75
Dying cell recognition shapes the pathophysiology of cell death. Cell Death Differ (2016) 0.75
IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget (2016) 0.75
Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. Oncotarget (2016) 0.75
Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. Oncoimmunology (2016) 0.75
Alpha Particles Induce Autophagy in Multiple Myeloma Cells. Front Med (Lausanne) (2015) 0.75
Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy. Viruses (2016) 0.75
Conditioning neoadjuvant therapies for improved immunotherapy of cancer. Biochem Pharmacol (2017) 0.75
Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness. Front Immunol (2017) 0.75
Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. Oncoimmunology (2017) 0.75
The immune response to secondary necrotic cells. Apoptosis (2017) 0.75
Cellular immunotherapies for cancer. Oncoimmunology (2017) 0.75
An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF(V600E) inhibitor-resistant metastatic melanoma cells. Autophagy (2017) 0.75
Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells. Biomed Res Int (2017) 0.75
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. Oncoimmunology (2017) 0.75
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J (2000) 41.48
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature (1999) 16.97
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods (1995) 16.00
Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol (2001) 13.98
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
The danger model: a renewed sense of self. Science (2002) 13.85
Mitochondrial membrane permeabilization in cell death. Physiol Rev (2007) 12.72
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature (2010) 11.24
Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med (1995) 10.91
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Autophagy in cell death: an innocent convict? J Clin Invest (2005) 10.70
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2008) 10.45
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood (1994) 9.10
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol (2008) 8.30
Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol (2010) 7.95
The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol (2009) 7.80
Natural adjuvants: endogenous activators of dendritic cells. Nat Med (1999) 7.10
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol (2005) 6.27
The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ (2011) 5.95
Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science (2010) 5.84
Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol (1998) 5.66
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol (2004) 5.13
High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol (2005) 5.04
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 4.98
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity (2008) 4.37
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol (2014) 4.28
Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med (1995) 4.20
CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity (2001) 4.16
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature (2010) 4.10
The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol (2008) 4.09
Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A (2009) 3.99
Danger signals: SOS to the immune system. Curr Opin Immunol (2001) 3.91
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc Natl Acad Sci U S A (2009) 3.57
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 3.41
Targeting the unfolded protein response in disease. Nat Rev Drug Discov (2013) 3.37
Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol (2006) 3.32
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev (2007) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cell death modalities: classification and pathophysiological implications. Cell Death Differ (2007) 3.19
The eIF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans. J Biol Chem (1993) 3.18
Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci (2007) 3.01
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol (2005) 2.96
The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol (2010) 2.93
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 2.89
Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem (2004) 2.81
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 2.81
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2.79
Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med (2012) 2.79
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity (2012) 2.72
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.52
Cell death assays for drug discovery. Nat Rev Drug Discov (2011) 2.51
Apoptotic cell removal in development and tissue homeostasis. Trends Immunol (2006) 2.51
The unfolded protein response: integrating stress signals through the stress sensor IRE1α. Physiol Rev (2011) 2.50
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 2.35
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol (2014) 2.28
Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol (2012) 2.28
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther (2000) 2.26
Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis (2006) 2.20
Analytical information obtainable by evaluation of the time course of firefly bioluminescence in the assay of ATP. Anal Biochem (1975) 2.11
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta (2009) 2.07
Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol (2011) 2.05
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis (2007) 2.04
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ (2008) 2.01
A dual role for autophagy in a murine model of lung cancer. Nat Commun (2014) 1.97
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol (2015) 0.86